|
POU5F1P4
|
Prostate carcinoma
|
0.100 |
Biomarker |
BEFREE |
However, reliable tools for detecting and targeting SOX2/OCT4-overexpressing cells are lacking, limiting our understanding of their roles in prostate cancer initiation, progression, and therapeutic resistance.
|
31500347 |
2019 |
|
POU5F1P4
|
Prostate carcinoma
|
0.100 |
AlteredExpression |
BEFREE |
Sphere formation and side population assays suggested that miR-1301-3p promoted the expansion of prostate cancer stem cells, and increased the expression of prostate cancer stem cell-associated genes, such as OCT4, SOX2, NANOG, CD44, KLF4, c-MYC, and MMP2.
|
29358129 |
2018 |
|
POU5F1P4
|
Prostate carcinoma
|
0.100 |
Biomarker |
BEFREE |
Furthermore, the combined targeting of CSCs and their interaction with TAMs by inhibiting ATG7/OCT4 and IL6 receptor effectively ameliorated ADT resistance in an orthotopic prostate cancer model.<b>Conclusions:</b> Targeting CSCs and their niche may prove to be a more powerful strategy than targeting CSCs alone, providing a rational approach to ameliorating ADT resistance in prostate cancer.<i></i>.
|
29691294 |
2018 |
|
POU5F1P4
|
Prostate carcinoma
|
0.100 |
AlteredExpression |
BEFREE |
The positive expression rate of CD147 and OCT4 were 100 and 77.38% in prostate cancer tissue, respectively, both markedly higher than in normal and benign prostate hyperplasia tissue (P ˂ 0.05).
|
26125892 |
2015 |
|
POU5F1P4
|
Prostate carcinoma
|
0.100 |
AlteredExpression |
BEFREE |
Aberrant methylation contributes to the reduced expression of OCT3 in prostate cancer.
|
22231567 |
2013 |
|
POU5F1P4
|
Prostate carcinoma
|
0.100 |
Biomarker |
BEFREE |
The prognostic function of OCT4 isoforms in PCa samples was examined by immunohistochemistry (IHC) and sensitivity and specificity of the antibodies used were evaluated by molecular biology techniques.
|
23636800 |
2013 |
|
POU5F1P4
|
Prostate carcinoma
|
0.100 |
AlteredExpression |
BEFREE |
We used the early transposon Oct4 and Sox2 enhancer (EOS) system to select human prostate cancer (PCA) cells expressing high levels of OCT4.
|
23600803 |
2013 |
|
POU5F1P4
|
Prostate carcinoma
|
0.100 |
AlteredExpression |
BEFREE |
Here, we have shown that hypoxia leads to increased expression of VEGF, IL-6, and CSC marker genes such as Nanog, Oct4 and EZH2, and also increased the expression of miR-21, an oncogenic miRNA, in prostate cancer (PCa) cells (PC-3 and LNCaP).
|
22952749 |
2012 |
|
POU5F1P4
|
Prostate carcinoma
|
0.100 |
Biomarker |
BEFREE |
DU145 and PC3 human prostate cancer cell lines (ATCC), tumor tissue from patients with prostate cancer and normal prostate tissue were evaluated for the reprogramming factors OCT3/4 (Cell Signaling Technology), SOX2, Klf4 (Santa Cruz Biotechnology, Santa Cruz, California), Nanog (BioLegend) and c-Myc (Cell Signaling) by semiquantitative reverse transcriptase-polymerase chain reaction, histological and immunohistochemical analysis.
|
20303530 |
2010 |
|
POU5F1P4
|
Prostate carcinoma
|
0.100 |
AlteredExpression |
BEFREE |
The objective of this study was to investigate the transcription and the protein expression of Oct 3/4 isoforms in prostate cancer and benign prostate tissue.
|
19274762 |
2009 |